-
-
-
-
-
-
-
Corcept Therapeutics (CORT) PT Raised to $105 at H.C. Wainwright
-
-
-
-
-
-
-
Wolfe Research Downgrades Corcept Therapeutics (CORT) to Underperform
-
-
-
-
-
-
-
Corcept submits European application for ovarian cancer treatment
-
-
-
-
-
-
-
Piper Sandler Reiterates OW Rating on Corcept Therapeutics (CORT) Following Expert Call
-
-
-
-
-
-
-
Piper Sandler Reiterates Overweight Rating on Corcept Therapeutics (CORT)
-
-
-
-
-
-
-
Corcept Therapeutics (CORT) PT Raised to $150 from $76 at Truist on 'Positive Ph3 ROSELLA Data'
-
-
-
-
-
-
-
Corcept Therapeutics (CORT) PT Raised to $115 at H.C. Wainwright
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

